4 Analysts Assess Thermo Fisher Scientific: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Thermo Fisher Scientific (TMO), with recent assessments showing a shift towards a more neutral stance. The average 12-month price target has increased to $605.5, reflecting a 14.82% rise. Key analysts from Citigroup, RBC Capital, Raymond James, and Barclays have updated their ratings and price targets, indicating a positive outlook despite recent revenue challenges. Thermo Fisher's financial performance shows strong profitability and efficient asset management, with a notable net margin and ROE.
March 18, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Thermo Fisher Scientific's average 12-month price target has been raised to $605.5, indicating a positive outlook from analysts despite a recent revenue decline of -4.93%. The company's strong net margin and ROE suggest robust financial health.
The increase in the average price target to $605.5 reflects a positive sentiment from analysts, suggesting a potential upside for TMO's stock price in the short term. Despite the revenue decline, the company's strong profitability metrics, such as a high net margin and ROE, support a bullish outlook. Analysts' updates, including raised price targets and ratings, further reinforce the expectation of stock price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100